TooNiceStocks.com Initiates Coverage on CorMedix ($CRMD)
TooNiceStocks Research put out an article on CorMedix Inc. (NYSE-AMEX: CRMD; Stock Twits; $CRMD). The reports notes that "interim data (will) be revealed in its phase II trial for its lead product, CRMD001 Deferiprone. CRMD001 will be used for the treatment of contrast-induced nephropathy". 
TNR goes on to state: "According to company updates for the year of 2010 and 4Q 2010, this preliminary data will be available in 1Q 2011, which is winding down rapidly. Data for the entire trial will be available in 2H 2011. An additional catalyst due out any time is the investigational device exemption approval by the FDA for CorMedix’s other key product, CRMD003 Neutrolin, to prevent catheter related bloodstream infections. This approval would allow CorMedix to initiate its medical device trial for this indication in which the company has already manufactured its first batch and started stability testing."
For the full report, please go to TooNiceStocks.com.
ProActive Capital Indexes
See ProActive's Disclaimer